Where Design Meets Biology: Engineering Multispecific TCEs & ADCs to Expand Therapeutic Index

• Leveraging combinatorial screening platforms for optimizing multispecific modalities
• Increasing tumor selectivity through novel conditionally active T-cell engagers
• Engineering logic-gated bispecific ADCs for enhanced target coverage or tumor selectivity

Speakers:

JD Bagert

Director, R&D

AstraZeneca